Hepatic Encephalopathy Nutrition Market Projected Growth Through 2036

Sales in this market are expected to increase from USD 210.1 million in 2025 to USD 224.2 million in 2026. Hepatic encephalopathy nutrition is designed to provide necessary protein, energy, and amino acids for patients with cirrhosis who cannot consume sufficient regular food. Recommendations from the American College of Gastroenterology in May 2025 promote adequate protein intake, particularly from plant-based or branched-chain amino acid (BCAA) enriched sources, and emphasize enteral nutrition when oral intake is insufficient. This guidance is leading to a higher adoption of clinical nutrition in cirrhosis treatments. Future Market Insights indicates a growing demand for easily preparable products that can be used at home, but challenges such as poor tolerance and unsuitable feeding methods might affect routine usage.

Regionally, the hepatic encephalopathy nutrition market in South Korea is expected to grow at a CAGR of 7.1% from 2026 to 2036, while the United States market is projected to rise at a CAGR of 6.2%. According to Statistics Korea, liver disease was among the top ten causes of death in 2025, highlighting the importance of nutrition in specialist hospitals. In the United States, there is greater availability of oral clinical nutrition through hospitals and outpatient channels. In contrast, South Korea's market growth is expected to be influenced by follow-up care and product refills after patient discharge.

Key insights include:

- Current liver-care guidance is promoting medically directed nutrition, as routine protein restriction is no longer advised for patients with hepatic encephalopathy.

- BCAA-enriched formulations are expected to hold a 47.7% share of the market in 2026, driven by the rising demand for liver-specific amino-acid nutrition.

- Powder sachets are predicted to constitute 44.6% of the product forms in 2026 due to their convenience for measured preparation and lower storage needs.

- Covert or Grade 1 hepatic encephalopathy is forecast to make up 46.8% of disease grading by 2026, aligning with longer periods of nutrition use among ambulatory patients.

Key players in the market include Otsuka Pharmaceutical, Fresenius Kabi, Abbott, Nestlé Health Science, Danone Nutricia, Ajinomoto, B. Braun, and Medtrition, all of which are enhancing their product offerings to address the growing need for hepatic encephalopathy nutrition.

Future analysts anticipate continued growth driven by a focus on home-based nutrition support and development of products that are easy to prepare and readily available. The market is segmented by formulation, product form, disease grade, end user, sales channel, and region.